Headlines about Curis (NASDAQ:CRIS) have been trending somewhat positive recently, AlphaOne Sentiment reports. The research firm, a subsidiary of Accern, rates the sentiment of news coverage by monitoring more than twenty million blog and news sources. AlphaOne ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Curis earned a news impact score of 0.07 on AlphaOne’s scale. AlphaOne also assigned news articles about the biotechnology company an impact score of 92 out of 100, meaning that recent news coverage is extremely likely to have an impact on the company’s share price in the near future.
Several equities research analysts have weighed in on the company. FBR & Co set a $6.00 target price on Curis and gave the stock a “buy” rating in a research report on Saturday, March 11th. Zacks Investment Research raised Curis from a “sell” rating to a “hold” rating in a report on Tuesday, March 14th. Finally, Cowen and Company reissued a “buy” rating on shares of Curis in a report on Wednesday, March 22nd. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Curis presently has a consensus rating of “Buy” and an average target price of $5.88.
Curis (NASDAQ:CRIS) opened at 1.66 on Friday. The company’s 50-day moving average price is $2.32 and its 200-day moving average price is $2.75. Curis has a 12-month low of $1.47 and a 12-month high of $3.72. The firm’s market capitalization is $238.66 million.
Curis (NASDAQ:CRIS) last posted its quarterly earnings data on Thursday, May 4th. The biotechnology company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.02. Curis had a negative net margin of 861.64% and a negative return on equity of 99.45%. The firm had revenue of $2.13 million during the quarter, compared to analysts’ expectations of $1.98 million. During the same quarter in the previous year, the company posted ($0.07) EPS. Curis’s revenue for the quarter was up 23.1% on a year-over-year basis. Equities analysts expect that Curis will post ($0.40) EPS for the current fiscal year.
In other Curis news, Director James R. Mcnab sold 76,276 shares of the business’s stock in a transaction on Friday, May 5th. The shares were sold at an average price of $2.04, for a total transaction of $155,603.04. Following the sale, the director now owns 879,688 shares of the company’s stock, valued at approximately $1,794,563.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director James R. Mcnab sold 146,694 shares of the business’s stock in a transaction on Thursday, April 27th. The shares were sold at an average price of $2.61, for a total transaction of $382,871.34. Following the sale, the director now directly owns 912,426 shares in the company, valued at approximately $2,381,431.86. The disclosure for this sale can be found here. In the last quarter, insiders sold 450,000 shares of company stock worth $1,101,973. 6.09% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: This piece was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://sportsperspectives.com/2017/05/20/somewhat-positive-news-coverage-extremely-likely-to-affect-curis-cris-stock-price-updated-updated-updated.html.
Curis Company Profile
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.